Is ZURA or URGN more profitable?

Zura Bio has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% Urogen Pharma -94.83% N/A -62.85%

Does the media prefer ZURA or URGN?

In the previous week, Zura Bio had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Zura Bio and 3 mentions for Urogen Pharma. Zura Bio's average media sentiment score of 1.07 beat Urogen Pharma's score of 0.94 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DMRA or ZURA?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A Zura Bio N/A N/A -$99.35M -$1.09 N/A

Is DMRA or ZURA more profitable?

Zura Bio's return on equity of -55.74% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Zura Bio N/A -55.74% -48.07%

Does the media favor DMRA or ZURA?

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Damora Therapeutics, Inc. Common Stock and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.07 beat Damora Therapeutics, Inc. Common Stock's score of 0.45 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or ZURA?

In the previous week, Sarepta Therapeutics had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Sarepta Therapeutics and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.07 beat Sarepta Therapeutics' score of 0.80 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NTLA or ZURA?

In the previous week, Zura Bio had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 4 mentions for Zura Bio and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.11 beat Zura Bio's score of 1.07 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ZURA or ANAB?

AnaptysBio has higher revenue and earnings than Zura Bio. AnaptysBio is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A AnaptysBio $234.60M 6.83 -$13.23M -$1.08 N/A

Is ZURA or ANAB more profitable?

Zura Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% AnaptysBio -11.53% N/A -7.75%

Does the media favor ZURA or ANAB?

In the previous week, AnaptysBio had 1 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for AnaptysBio and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.07 beat AnaptysBio's score of 1.00 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zura Bio (ZURA) Competitors

$5.23 -0.06 (-1.13%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.22 -0.01 (-0.10%)

As of 07/24/2026 07:34 PM Eastern

Compare

ZURA vs. URGN, DMRA, SRPT, NTLA, and ANAB

Should you buy Zura Bio stock or one of its competitors? MarketBeat compares Zura Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zura Bio include Urogen Pharma (URGN), Damora Therapeutics, Inc. Common Stock (DMRA), Sarepta Therapeutics (SRPT), Intellia Therapeutics (NTLA), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry.

How does Zura Bio compare to Urogen Pharma?

Zura Bio (NASDAQ:ZURA) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Zura Bio currently has a consensus price target of $10.75, suggesting a potential upside of 105.54%. Urogen Pharma has a consensus price target of $41.63, suggesting a potential upside of 1.60%. Given Zura Bio's higher possible upside, equities analysts clearly believe Zura Bio is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Zura Bio has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Urogen Pharma	$109.79M	18.18	-$153.49M	-$2.75	N/A

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Zura Bio had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Zura Bio and 3 mentions for Urogen Pharma. Zura Bio's average media sentiment score of 1.07 beat Urogen Pharma's score of 0.94 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zura Bio has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Urogen Pharma	-94.83%	N/A	-62.85%

Zura Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Summary

Zura Bio beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 12.4% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Damora Therapeutics, Inc. Common Stock and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.07 beat Damora Therapeutics, Inc. Common Stock's score of 0.45 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zura Bio's return on equity of -55.74% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Zura Bio	N/A	-55.74%	-48.07%

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.43, indicating a potential upside of 47.22%. Zura Bio has a consensus target price of $10.75, indicating a potential upside of 105.54%. Given Zura Bio's higher possible upside, analysts clearly believe Zura Bio is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Zura Bio beats Damora Therapeutics, Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 12.4% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Sarepta Therapeutics had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Sarepta Therapeutics and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.07 beat Sarepta Therapeutics' score of 0.80 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics currently has a consensus target price of $23.90, suggesting a potential upside of 52.45%. Zura Bio has a consensus target price of $10.75, suggesting a potential upside of 105.54%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	7 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Zura Bio has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Zura Bio	N/A	-55.74%	-48.07%

Zura Bio has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.75	-$713.41M	-$0.96	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Sarepta Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Summary

Sarepta Therapeutics and Zura Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Zura Bio has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Zura Bio's return on equity of -55.74% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Zura Bio	N/A	-55.74%	-48.07%

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Intellia Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $20.19, suggesting a potential upside of 88.14%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 105.54%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Zura Bio has lower revenue, but higher earnings than Intellia Therapeutics. Zura Bio is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	22.15	-$412.69M	-$3.54	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

In the previous week, Zura Bio had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 4 mentions for Zura Bio and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.11 beat Zura Bio's score of 1.07 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zura Bio beats Intellia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Zura Bio compare to AnaptysBio?

Zura Bio (NASDAQ:ZURA) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Zura Bio presently has a consensus target price of $10.75, suggesting a potential upside of 105.54%. AnaptysBio has a consensus target price of $82.00, suggesting a potential upside of 51.43%. Given Zura Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zura Bio is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, AnaptysBio had 1 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for AnaptysBio and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.07 beat AnaptysBio's score of 1.00 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Zura Bio shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zura Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
AnaptysBio	-11.53%	N/A	-7.75%

Zura Bio has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Zura Bio. AnaptysBio is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
AnaptysBio	$234.60M	6.83	-$13.23M	-$1.08	N/A

Summary

AnaptysBio beats Zura Bio on 9 of the 16 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$501.92M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-4.80	21.11	27.00	23.71
Price / Sales	N/A	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	3.79	7.88	10.28	6.07
Net Income	-$99.35M	$23.81M	$3.60B	$331.84M
7 Day Performance	-4.04%	-3.79%	-1.25%	-1.53%
1 Month Performance	15.20%	-2.59%	-0.35%	-2.46%
1 Year Performance	218.90%	32.85%	18.41%	13.66%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.8858 of 5 stars	$5.23 -1.1%	$10.75 +105.5%	+211.3%	$501.92M	N/A	N/A	3	News Coverage
URGN Urogen Pharma	1.96 of 5 stars	$39.19 -0.8%	$39.50 +0.8%	+127.6%	$1.91B	$109.79M	N/A	200	Analyst Forecast
DMRA Damora Therapeutics, Inc. Common Stock	2.1998 of 5 stars	$30.99 +10.7%	$42.43 +36.9%	+649.5%	$1.91B	N/A	N/A	40	Analyst Forecast Gap Up
SRPT Sarepta Therapeutics	2.9991 of 5 stars	$17.96 -4.6%	$25.09 +39.7%	+21.6%	$1.90B	$2.20B	N/A	1,372
NTLA Intellia Therapeutics	3.6615 of 5 stars	$13.30 +2.2%	$20.67 +55.4%	-16.0%	$1.86B	$67.67M	N/A	600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors

ZURA vs. URGN, DMRA, SRPT, NTLA, and ANAB

How does Zura Bio compare to Urogen Pharma?

Summary

How does Zura Bio compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Zura Bio compare to Sarepta Therapeutics?

Summary

How does Zura Bio compare to Intellia Therapeutics?

Summary

How does Zura Bio compare to AnaptysBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zura Bio (ZURA) Competitors

ZURA vs. URGN, DMRA, SRPT, NTLA, and ANAB

How does Zura Bio compare to Urogen Pharma?

Do analysts rate ZURA or URGN?

Which has preferable valuation and earnings, ZURA or URGN?

Do institutionals and insiders have more ownership in ZURA or URGN?

Does the media prefer ZURA or URGN?

Is ZURA or URGN more profitable?

Which has more risk and volatility, ZURA or URGN?

Summary

How does Zura Bio compare to Damora Therapeutics, Inc. Common Stock?

Which has more risk and volatility, DMRA or ZURA?

Do institutionals & insiders believe in DMRA or ZURA?

Does the media favor DMRA or ZURA?

Is DMRA or ZURA more profitable?

Which has better valuation & earnings, DMRA or ZURA?

Do analysts recommend DMRA or ZURA?

Summary

How does Zura Bio compare to Sarepta Therapeutics?

Do institutionals and insiders hold more shares of SRPT or ZURA?

Does the media prefer SRPT or ZURA?

Do analysts rate SRPT or ZURA?

Is SRPT or ZURA more profitable?

Which has stronger valuation and earnings, SRPT or ZURA?

Which has more volatility & risk, SRPT or ZURA?

Summary

How does Zura Bio compare to Intellia Therapeutics?

Is NTLA or ZURA more profitable?

Do institutionals & insiders hold more shares of NTLA or ZURA?

Which has more volatility and risk, NTLA or ZURA?

Do analysts rate NTLA or ZURA?

Which has preferable earnings & valuation, NTLA or ZURA?

Does the media favor NTLA or ZURA?

Summary

How does Zura Bio compare to AnaptysBio?

Do analysts recommend ZURA or ANAB?

Does the media favor ZURA or ANAB?

Do insiders and institutionals have more ownership in ZURA or ANAB?

Is ZURA or ANAB more profitable?

Which has more volatility & risk, ZURA or ANAB?

Which has higher earnings & valuation, ZURA or ANAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools